Table 3.
Influencing variables of the Patient Benefit Index (PBI) in patients with psoriasis (PSO) (n = 82), using univariate regression analyses.
| Beta | T | P | 95% CI | |
|---|---|---|---|---|
| Age | − 0.091 | − 0.814 | 0.418 | − 0.312, 0.131 |
|
F(1,81) = 0.662, p = .418 Corr. R2 = − 0.004 | ||||
| Sex | − 0.315 | -2.970 | 0.004** | -1.094, − 0.216 |
|
F(1,81) = 8.819, p = .004 Corr. R2 = 0.088 | ||||
| Delta BSA | − 0.303 | -2.840 | 0.006** | − 0.515, − 0.091 |
|
F(1,81) = 8.067, p = .006 Corr. R2 = 0.08 | ||||
| Delta SAPASI | − 0.246 | -2.064 | 0.043* | − 0.458, − 0.008 |
|
F(1,67) = 4.260, p = .043 Corr. R2 = 0.046 |
||||
| Delta DLQI | − 0.587 | -6.486 | < 0.001*** | − 0.767, − 0.407 |
|
F(1,81) = 42.066, p < .001 Corr. R2 = 0.336 | ||||
| Delta HADS | − 0.363 | -3.490 | < 0.001*** | − 0.571, − 0.156 |
|
F(1,81) = 12.180 p < .001 Corr. R2 = 0.121 | ||||
| Type of therapy (phototherapy/conventional systemic vs. biologics) | 0.309 | 2.902 | 0.005** | 0.196, 1.050 |
|
F(1,81) = 8.421, p = .005 Corr. R2 = 0.084 | ||||
| Number of prior dermatologic treatments | 0.026 | 0.228 | 0.820 | − 0.197, 0.248 |
|
F(1,81) = 0.052, p = .820 Corr. R2 = − 0.012 |
*p ≤ .05, ** p ≤ .01, ***p ≤ .001.